<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683889</url>
  </required_header>
  <id_info>
    <org_study_id>17-2336</org_study_id>
    <nct_id>NCT02683889</nct_id>
  </id_info>
  <brief_title>Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation</brief_title>
  <official_title>The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of Acthar in patients to undergo renal transplantation and&#xD;
      will measure the rate of FSGS recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study enrolling renal transplant recipients with the primary native&#xD;
      kidney disease of FSGS.&#xD;
&#xD;
      Primary endpoint is rate of recurrence of FSGS as seen in renal transplant biopsies and in&#xD;
      rate of proteinuria. Secondary endpoint is renal function after transplantation The target&#xD;
      subject number is 20 patients and the target population is primary FSGS patients. By the&#xD;
      current data, FSGS should recur in 23% of patients. Therefore, it would be expected that at&#xD;
      least 4 patients will develop recurrent FSGS after renal transplantation.&#xD;
&#xD;
      Screening will be performed by the Principal Investigator during the kidney transplant&#xD;
      evaluation clinics and during the wait list kidney transplant evaluation clinic. All patients&#xD;
      with FSGS will have maintenance immunosuppression with belatacept (if EBV positive), prograf,&#xD;
      cellcept and prednisone. If after one year the patient has been stable and there has not been&#xD;
      rejection, will stop the prograf and continue solely with belatacept, cellcept and&#xD;
      prednisone.&#xD;
&#xD;
      Dosage and Administration of Acthar The dose of acthar to be given to every enrolled patient&#xD;
      will be 80 units twice a week for 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrence of FSGS as seen in renal transplant biopsies proteinuria</measure>
    <time_frame>2 years</time_frame>
    <description>This will be studied in the renal transplant biopsies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of recurrence of proteinuria</measure>
    <time_frame>2 years</time_frame>
    <description>By measurement of urine protein and urine creatinine ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function after transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>By measurement of the estimated glomerular filtration rate with patient's creatinine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>FSGS</condition>
  <arm_group>
    <arm_group_label>One arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS</description>
    <arm_group_label>One arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FSGS&#xD;
&#xD;
          -  To receive either a live donor or deceased donor kidney transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not having FSGS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica B Grafals, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Grafals, MD, MPH</last_name>
    <phone>720 848 2237</phone>
    <email>MONICA.GRAFALS@CUANSCHUTZ.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medstar Georgetown Transplant Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Grafals, MD, MPH</last_name>
      <phone>202-444-3700</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02683889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

